Forma Therapeutics Holdings, Inc. FMTX
We take great care to ensure that the data presented and summarized in this overview for Forma Therapeutics Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in FMTX
Top Purchases
Top Sells
About FMTX
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Insider Transactions at FMTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 14
2022
|
Ra Capital Management, L.P. Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
9,018,901
-100.0%
|
-
|
|
Oct 14
2022
|
Timothy P Clackson Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
30,840
-100.0%
|
-
|
|
Oct 14
2022
|
Peter Wirth Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
134,915
-100.0%
|
-
|
|
Oct 14
2022
|
Thomas G Wiggans Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
7,250
-100.0%
|
-
|
|
Oct 14
2022
|
Todd Shegog SVP, Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
56,143
-100.0%
|
-
|
|
Oct 14
2022
|
John E Bishop SVP, Chief Technology Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
47,950
-100.0%
|
-
|
|
Oct 14
2022
|
Agustin Melian EVP, Research & Development |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
79,000
-100.0%
|
-
|
|
Oct 14
2022
|
Arturo Md Molina Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,000
-100.0%
|
-
|
|
Oct 14
2022
|
Frank D. Lee President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
201,436
-100.0%
|
-
|
|
Oct 14
2022
|
Wayne A.I. Frederick Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
7,250
-100.0%
|
-
|
|
Oct 14
2022
|
Marsha Fanucci Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
59,782
-100.0%
|
-
|
|
Oct 14
2022
|
Jeannette Potts Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
47,358
-100.0%
|
-
|
|
Oct 14
2022
|
Brian Andrew Lesser SVP, Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
52,593
-100.0%
|
-
|
|
Jul 11
2022
|
Agustin Melian EVP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
79,000
+50.0%
|
-
|
|
Jun 08
2022
|
Arturo Md Molina Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+31.03%
|
-
|
|
Jun 08
2022
|
Marsha Fanucci Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+7.0%
|
-
|
|
Jun 08
2022
|
Timothy P Clackson Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+12.73%
|
-
|
|
Jun 08
2022
|
Peter Wirth Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+3.23%
|
-
|
|
Jun 08
2022
|
Thomas G Wiggans Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+38.3%
|
-
|
|
Jun 08
2022
|
Selwyn M Md Vickers Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+38.3%
|
-
|